We are live on ! Find out more
N

Nuveen Portfolio holdings

AUM $369B
1-Year Est. Return 31.66%
This Fund
S&P 500
This Quarter Est. Return
+9.39%
1 Year Est. Return
+31.66%
3 Year Est. Return
+110.02%
5 Year Est. Return
+148.02%
10 Year Est. Return
+492.84%
AUM
$335B
AUM Growth
+$21B
Cap. Flow
-$4B
Cap. Flow %
-1.19%
Top 10 Hldgs %
21.52%
Holding
3,670
New
323
Increased
1,420
Reduced
1,524
Closed
323

Top Sells

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$1.66B
2
BABA icon
Alibaba
BABA
+$881M
3
INTC icon
Intel
INTC
+$783M
4
GOOG icon
Alphabet (Google) Class C
GOOG
+$783M
5
LIN icon
Linde
LIN
+$667M

Sector Composition

Rank Sector Weight
1 Technology 23.8%
2 Financials 13%
3 Consumer Discretionary 12.7%
4 Healthcare 12.61%
5 Communication Services 10.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
GPX
2951
DELISTED
GP Strategies Corp.
GPX
$1.1M ﹤0.01%
69,917
-6,431
-8% -$104K
HMTV
2952
DELISTED
Hemisphere Media Group, Inc.
HMTV
$1.09M ﹤0.01%
92,666
+8,070
+10% +$100K
FRST icon
2953
Primis Financial Corp
FRST
$404M
$1.09M ﹤0.01%
+115,482
New +$1.73M
JOAN
2954
DELISTED
JOANN, Inc. Common Stock
JOAN
$1.08M ﹤0.01%
+68,717
New +$941K
STXB
2955
DELISTED
Spirit of Texas Bancshares, Inc. Common Stock
STXB
$1.08M ﹤0.01%
47,165
+5,654
+14% +$131K
DRIO icon
2956
DarioHealth
DRIO
$71.2M
$1.07M ﹤0.01%
+2,507
New +$955K
APYX icon
2957
Apyx Medical
APYX
$171M
$1.06M ﹤0.01%
103,249
-25,364
-20% -$251K
PRLD icon
2958
Prelude Therapeutics
PRLD
$390M
$1.06M ﹤0.01%
37,159
-187
-0.5% -$6.66K
DAKT icon
2959
Daktronics
DAKT
$1.04B
$1.06M ﹤0.01%
161,346
-3,529
-2% -$23.1K
LITS
2960
Lite Strategy Inc
LITS
$30.9M
$1.06M ﹤0.01%
18,604
-1,284
-6% -$82.5K
JNCE
2961
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$1.06M ﹤0.01%
155,761
+29,838
+24% +$248K
COGT icon
2962
Cogent Biosciences
COGT
$7.24B
$1.05M ﹤0.01%
+129,850
New +$1.1M
BNTX icon
2963
BioNTech
BNTX
$23.5B
$1.05M ﹤0.01%
4,699
-98
-2% -$18.5K
RMO
2964
DELISTED
Romeo Power, Inc.
RMO
$1.05M ﹤0.01%
+129,113
New +$1.1M
OYST
2965
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
$1.05M ﹤0.01%
60,851
+11,247
+23% +$214K
VCTR icon
2966
Victory Capital Holdings
VCTR
$6.65B
$1.04M ﹤0.01%
32,119
+18,557
+137% +$542K
HBIO icon
2967
Harvard Bioscience
HBIO
$29.2M
$1.03M ﹤0.01%
12,416
-5,082
-29% -$360K
BHR
2968
Braemar Hotels & Resorts
BHR
$142M
$1.03M ﹤0.01%
+166,083
New +$1.02M
IHC
2969
DELISTED
Independence Holding Company
IHC
$1.03M ﹤0.01%
22,207
-1,326
-6% -$58.8K
SMMF
2970
DELISTED
Summit Financial Group, Inc.
SMMF
$1.03M ﹤0.01%
46,747
+1,400
+3% +$34.3K
PBYI icon
2971
Puma Biotechnology
PBYI
$454M
$1.02M ﹤0.01%
111,404
-132,963
-54% -$1.35M
ETNB
2972
DELISTED
89bio
ETNB
$1.02M ﹤0.01%
54,614
-10,298
-16% -$230K
INVE icon
2973
Identive
INVE
$61.9M
$1.01M ﹤0.01%
+59,687
New +$902K
GCMG icon
2974
GCM Grosvenor
GCMG
$820M
$1.01M ﹤0.01%
+97,255
New +$1.15M
PRTK
2975
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$1.01M ﹤0.01%
148,543
-10,342
-7% -$83.6K

Similar funds

Nuveen's Q2 2021 Portfolio in Review

As of Q2 2021, Nuveen held 3,670 positions worth $335B, up 6.7% from $314B the previous quarter. Its ten largest holdings account for 22% of the portfolio.

Nuveen's Q2 2021 filing shows 323 new, 1,420 increased, 1,524 reduced and 323 closed positions. Its largest new stake was UiPath: 2,457,331 shares worth $167M. The largest sale was Apple, an estimated $1.66B.

By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 23% a quarter earlier, followed by Financials and Consumer Discretionary.

  • Nuveen's largest Q2 2021 buy was UiPath: 2,457,331 shares worth $167M.
  • Nuveen added most to Wells Fargo in Q2 2021, an estimated $512M increase.
  • Nuveen's biggest Q2 2021 reduction was Apple, cutting an estimated $1.66B.
  • Nuveen fully exited SolarEdge in Q2 2021, selling an estimated $66M.
  • Nuveen's ten largest holdings make up 22% of its $335B portfolio in Q2 2021.
  • Nuveen opened 323 new positions and closed 323 in Q2 2021.
  • Nuveen's portfolio value rose 6.7% quarter-over-quarter to $335B.

Based on Nuveen's 13F filing for Q2 2021, filed 16 Aug 2021.